Differential Expression of S1P Receptor Subtypes in Human Bladder Transitional Cell Carcinoma

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2019 Feb 4

PMID 30712233

Citations 6

Authors

A Palangi

N Shakhssalim

M Parvin

S Bayat

A Allameh

Affiliations

Soon will be listed here.

Abstract

Purpose: Sphingosine 1 phosphate (S1P), S1P receptors (S1PRs) and their signaling pathways play an important role in the fate of cancer cells. The expression pattern of S1PR subtypes (S1PR1-S1PR5) may alter in cancer development stages, depending on the origin and the pathologic features of tumors. The present study aimed to examine the relationship between plasma S1P levels and the expression of S1PR subtypes in bladder tumors.

Methods/patients: These changes were evaluated in terms of the pathologic grades and stages of human bladder cancer samples. For this, tumor biopsies from 41 new bladder cancer patients as well as 26 normal-looking bladder tissues were collected and processed for immunohistochemistry (IHC) and quantitative real-time RT-PCR of S1PR subtypes. Plasma S1P level was measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS).

Results: The results show that tissue S1PR1, S1PR2 and S1PR3 are over-expressed in all tumors regardless of their pathological grade (~ 3, ~ 6 and ~ 104 folds, respectively). These results were corroborated by IHC data showing accumulation of S1PR subtypes 1 and 2 in the tissues. Plasma S1P in the plasma samples from patients was in the range of control samples (Controls; 256 ± 47; patients, 270 ± 41).

Conclusions: Overexpression of S1PR1, S1PR2 and S1PR3 in bladder tumor biopsies which were corroborated with the pathological grades and stages may suggest that S1PR profile in tumor biopsies is a promising marker in the diagnosis of bladder carcinoma.

Citing Articles

Urothelial Urinary Bladder Cancer Is Characterized by Stage-Dependent Aberrations in Metabolism of Bioactive Sphingolipids.

Mlynarczyk G, Miklosz A, Chabowski A, Baranowski M Int J Mol Sci. 2024; 25(22).

PMID: 39595959 PMC: 11594108. DOI: 10.3390/ijms252211889.

Down-regulation of key regulatory factors in sphingosine-1-phosphate (S1P) pathway in human lung fibroblasts transfected with selected microRNAs.

Allameh A, Atashbasteh M, Mortaz E, Naeeni B, Jafari-Khorchani M Mol Biol Res Commun. 2024; 13(4):201-209.

PMID: 39315290 PMC: 11416850. DOI: 10.22099/mbrc.2024.49810.1951.

Adiponectin Modulates Smooth Muscle Cell Morpho-Functional Properties in Murine Gastric Fundus via Sphingosine Kinase 2 Activation.

Garella R, Bernacchioni C, Chellini F, Tani A, Palmieri F, Parigi M Life (Basel). 2023; 13(9).

PMID: 37763216 PMC: 10532860. DOI: 10.3390/life13091812.

Targeting May Result in Enhanced Migration of Cancer Cells in Bladder Carcinoma.

Chen C, Meng E, Wu S, Lai H, Lu Y, Yang M Cancers (Basel). 2021; 13(17).

PMID: 34503284 PMC: 8431630. DOI: 10.3390/cancers13174474.

Genetic and molecular biology of bladder cancer among Iranian patients.

Mojarrad M, Moghbeli M Mol Genet Genomic Med. 2020; 8(6):e1233.

PMID: 32253828 PMC: 7284045. DOI: 10.1002/mgg3.1233.

References

Goetzl E, Dolezalova H, Kong Y, Zeng L . Dual mechanisms for lysophospholipid induction of proliferation of human breast carcinoma cells. Cancer Res. 1999; 59(18):4732-7. View

Yamaguchi H, Kitayama J, Takuwa N, Arikawa K, Inoki I, Takehara K . Sphingosine-1-phosphate receptor subtype-specific positive and negative regulation of Rac and haematogenous metastasis of melanoma cells. Biochem J. 2003; 374(Pt 3):715-22. PMC: 1223636. DOI: 10.1042/BJ20030381. View

Van Brocklyn J, Young N, Roof R . Sphingosine-1-phosphate stimulates motility and invasiveness of human glioblastoma multiforme cells. Cancer Lett. 2003; 199(1):53-60. DOI: 10.1016/s0304-3835(03)00334-3. View

Rosen H, Goetzl E . Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat Rev Immunol. 2005; 5(7):560-70. DOI: 10.1038/nri1650. View

Yamashita H, Kitayama J, Shida D, Yamaguchi H, Mori K, Osada M . Sphingosine 1-phosphate receptor expression profile in human gastric cancer cells: differential regulation on the migration and proliferation. J Surg Res. 2005; 130(1):80-7. DOI: 10.1016/j.jss.2005.08.004. View

Schmidt H, Schmidt R, Geisslinger G . LC-MS/MS-analysis of sphingosine-1-phosphate and related compounds in plasma samples. Prostaglandins Other Lipid Mediat. 2006; 81(3-4):162-70. DOI: 10.1016/j.prostaglandins.2006.09.003. View

Schmittgen T, Livak K . Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3(6):1101-8. DOI: 10.1038/nprot.2008.73. View

Vadas M, Xia P, McCaughan G, Gamble J . The role of sphingosine kinase 1 in cancer: oncogene or non-oncogene addiction?. Biochim Biophys Acta. 2008; 1781(9):442-7. DOI: 10.1016/j.bbalip.2008.06.007. View

Mitra A, Cote R . Molecular pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol. 2008; 4:251-85. DOI: 10.1146/annurev.pathol.4.110807.092230. View

10.

Takabe K, Kim R, Allegood J, Mitra P, Ramachandran S, Nagahashi M . Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2. J Biol Chem. 2010; 285(14):10477-86. PMC: 2856255. DOI: 10.1074/jbc.M109.064162. View

11.

Leong W, Saba J . S1P metabolism in cancer and other pathological conditions. Biochimie. 2010; 92(6):716-23. PMC: 2878883. DOI: 10.1016/j.biochi.2010.02.014. View

12.

Taylor S, Wakem M, Dijkman G, Alsarraj M, Nguyen M . A practical approach to RT-qPCR-Publishing data that conform to the MIQE guidelines. Methods. 2010; 50(4):S1-5. DOI: 10.1016/j.ymeth.2010.01.005. View

13.

Pyne N, Pyne S . Sphingosine 1-phosphate and cancer. Nat Rev Cancer. 2010; 10(7):489-503. DOI: 10.1038/nrc2875. View

14.

Maceyka M, Harikumar K, Milstien S, Spiegel S . Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol. 2011; 22(1):50-60. PMC: 3253987. DOI: 10.1016/j.tcb.2011.09.003. View

15.

Nunes J, Naymark M, Sauer L, Muhammad A, Keun H, Sturge J . Circulating sphingosine-1-phosphate and erythrocyte sphingosine kinase-1 activity as novel biomarkers for early prostate cancer detection. Br J Cancer. 2012; 106(5):909-15. PMC: 3305969. DOI: 10.1038/bjc.2012.14. View

16.

Frantzi M, Makridakis M, Vlahou A . Biomarkers for bladder cancer aggressiveness. Curr Opin Urol. 2012; 22(5):390-6. DOI: 10.1097/MOU.0b013e328356ad0e. View

17.

Pignot G, Cizeron-Clairac G, Vacher S, Susini A, Tozlu S, Vieillefond A . microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. Int J Cancer. 2012; 132(11):2479-91. DOI: 10.1002/ijc.27949. View

18.

Liang J, Nagahashi M, Kim E, Harikumar K, Yamada A, Huang W . Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell. 2013; 23(1):107-20. PMC: 3578577. DOI: 10.1016/j.ccr.2012.11.013. View

19.

Babjuk M, Burger M, Zigeuner R, Shariat S, van Rhijn B, Comperat E . EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013; 64(4):639-53. DOI: 10.1016/j.eururo.2013.06.003. View

20.

Fernandez-Marcos P, Serrano M, Maraver A . Bladder cancer and the Notch pathway. Oncotarget. 2015; 6(3):1346-7. PMC: 4359298. DOI: 10.18632/oncotarget.3183. View